ClearBridge LLC (Maryland)’s Ultragenyx Pharmaceutical RARE Stock Holding History

ClearBridge LLC (Maryland)’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,097	Closed	-$56K	–	194
2018 Q1	$56K	Hold	1,097	–	–	﹤0.01%	174
2017 Q4	$51K	Hold	1,097	–	–	﹤0.01%	174
2017 Q3	$58K	Hold	1,097	–	–	﹤0.01%	171
2017 Q2	$68K	Buy	1,097 +77	+8%	+$4.64K	﹤0.01%	167
2017 Q1	$69K	Hold	1,020	–	–	﹤0.01%	171
2016 Q4	$72K	Hold	1,020	–	–	﹤0.01%	168
2016 Q3	$72K	Buy	+1,020	New	+$65.1K	﹤0.01%	170

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge LLC (Maryland)'s RARE Position: Q2 2018 in Review

ClearBridge LLC (Maryland) sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2018, closing a stake of 1,097 shares — an estimated $56K sold.

ClearBridge LLC (Maryland) first reported a position in RARE in Q3 2016 and held it in 7 quarters. The position peaked at $72K in Q4 2016. 158 funds tracked by Wall St. Rank hold RARE as of Q2 2018.

ClearBridge LLC (Maryland) reported no remaining Ultragenyx Pharmaceutical position as of Q2 2018 after selling out during the quarter.
ClearBridge LLC (Maryland) sold 1,097 Ultragenyx Pharmaceutical shares in Q2 2018, an estimated $56K.
ClearBridge LLC (Maryland) first reported a position in Ultragenyx Pharmaceutical in Q3 2016 and held it in 7 quarters.
ClearBridge LLC (Maryland)'s Ultragenyx Pharmaceutical position peaked at $72K in Q4 2016.
158 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2018.

Based on ClearBridge LLC (Maryland)'s 13F filing for Q2 2018, filed 14 Aug 2018.